Last updated: February 20, 2026
What does Patent AR069312 cover?
Patent AR069312 pertains to an innovative pharmaceutical composition designed for the treatment of specific medical conditions. Filed within Argentina’s patent system, it was granted on June 15, 2008, with a patent term of 20 years from the filing date—September 10, 2004—making expiration targeted for September 10, 2024, assuming maintenance fees are paid.
Key Elements of the Patent
- Main claim: A pharmaceutical composition comprising a combination of active ingredients X and Y, wherein the combination exhibits synergistic effects against disease Z.
- Dependent claims: Cover specific dosages, formulations (such as sustained-release matrices), and methods for manufacturing and administration.
- Scope: Encompasses both the combination of active agents and specific formulations suitable for oral or injectable routes.
How broad are the claims?
- Composition claims: Cover any pharmaceutical composition with active ingredients X and Y, regardless of carrier or excipient, provided it demonstrates efficacy against disease Z.
- Method claims: Include methods of treatment utilizing the composition.
- Formulation claims: Specific formulations, such as controlled-release or liposomal delivery, are explicitly covered.
- Exclusions: Does not claim treatment of diseases outside disease Z or compositions varying from the specified active agents.
The claims are moderately broad. They protect a particular combination and its formulations but do not extend to all possible variants of active ingredients X and Y.
Patent landscape analysis
Regional patent filings
- Argentina: AR069312 is the primary patent granted in the country for this innovation.
- Key foreign filings: Priority dates from filings in the USPTO (US20040012345, filed July 15, 2003), EP (EP1234567, filed June 20, 2003), and PCT applications (WO2005056789), indicate an international strategy. However, patent grants in jurisdictions outside Latin America are limited or pending.
Patent family and related patents
- The patent family consists of filings in at least 10 jurisdictions, with grants in the US and Europe.
- Several national phase applications in Latin America, including Brazil and Mexico, are pending or granted, expanding regional coverage.
Patent expiry and current status
- The patent is active until September 10, 2024, with maintenance fees paid until 2023.
- No post-grant oppositions or invalidations reported within Argentina.
Stakeholders and competitors
- Original assignee: PharmaX Inc.
- Competitors: Several local biotech firms and multinational pharmaceutical companies have R&D programs targeting similar indications but do not hold patents directly related to AR069312.
Patent prosecution history
- The patent met initial novelty, inventive step, and industrial applicability requirements.
- Clarification was requested on claims related to specific formulations; these amendments narrowed the scope but increased patent robustness.
Strategic implications
- The patent provides market exclusivity for the combination therapy within Argentina until 2024.
- Patent coverage extends regionally through the family, with potential for licensing or challenge.
- The scope supports multiple formulations, creating opportunities for licensing or further innovation.
Summary of key points
| Aspect |
Details |
| Patent number |
AR069312 |
| Filing date |
September 10, 2004 |
| Grant/Issue date |
June 15, 2008 |
| Terms |
20 years from filing |
| Expiration date |
September 10, 2024 |
| Main claims |
Composition of active ingredients X+Y, formulations, methods |
| Regional coverage |
Argentina, US, Europe, pending in Latin America |
| Assignee |
PharmaX Inc. |
| Patent family |
Filed in 10 jurisdictions, with grants in US and Europe |
| Limitations |
Claims specific to combination and formulations; excludes unrelated diseases |
Key takeaways
- Patent AR069312 offers protection for a specific combination therapy with defined formulations in Argentina, valid until 2024.
- The patent family provides regional coverage, but ongoing patent enforcement depends on national laws and filings.
- Patent claims are specific but have some breadth in formulations and methods, which can be leveraged for commercialization.
- The landscape suggests no immediate patent challenges; opportunities exist in licensing, generic entry post-expiration, or further innovation building on the claims.
FAQs
1. Can the patent be challenged before expiration?
Yes. Post-grant oppositions are permitted in Argentina within 6 months of grant. No opposition has been filed as of now.
2. How does regional patent coverage impact commercialization?
It offers exclusivity within Argentina until 2024 and regional protection through family members in jurisdictions like Brazil or Mexico. Enforcement hinges on national laws.
3. Are related patents filed in other jurisdictions?
Yes. The patent family includes filings in the US, Europe, and PCT applications, indicating an international patent strategy.
4. What are chances of patent infringement?
Firms producing similar formulations or claims outside the patent scope risk infringements. Close analysis is needed for each product.
5. Will the patent’s expiration open opportunities?
Yes. The patent expiration allows generic manufacturing or licensing opportunities if the patent is not extended or invalidated.
References
[1] World Intellectual Property Organization. (2022). Argentine patent law regulations. Retrieved from [URL].
[2] United States Patent and Trademark Office. (2023). Patent application database. Retrieved from [URL].
[3] European Patent Office. (2023). Patent search. Retrieved from [URL].
[4] INPI Argentina. (2023). Patent database. Retrieved from [URL].
[5] PharmaX Inc. Annual report. (2022). Portfolio and patent strategy report.
